Fluidigm announces new integrated fluidic circuits for single-cell genomics on the C1™ system

Fluidigm announced new integrated fluidic circuits (IFCs) that will increase the number of single cells that can be isolated and analyzed on the C1™ system. Bringing together the trusted Fluidigm® C1 single-cell isolation system with the benefits of a growing suite of optimized microfluidic circuits, researchers can confidently expand their single-cell studies while taking advantage of well-established, industry-proven workflows.

Single-cell research is fast becoming a technology standard in basic and translational research, biomarker discovery, and therapeutic development. Using single-cell approaches, researchers are visualizing biological systems with unprecedented resolution using RNA, DNA, epigenetic, and protein markers to uncover novel cellular subpopulations and networks that control human health and disease. Enabling the largest suite of integrated single-cell analysis workflows in the industry, the C1 has been used by leading research institutions around the world to advance immunology, cancer, neuroscience, and stem cell research.

We are very pleased to announce the release of new medium-cell (10–17 µm) IFCs designed to capture up to 96 cells with higher single-cell capture efficiency. These new IFCs have been extensively tested both internally and at customer sites, demonstrating significantly improved single-cell capture performance. We plan to initiate customer shipments by the end of this month and are confident our customers will be very pleased with their performance,” said Gajus Worthington, CEO of Fluidigm. “Supporting our continued commitment to provide a wide range of high-quality workflows for single-cell characterization, we also plan to release two new high throughput IFCs on the C1 system this year to enable screening of larger cell populations at single cell resolution.”

High-quality workflows for medium-to-large-scale single-cell studies are essential to identifying rare cell populations. This has become especially important in the highly funded areas of immunology and cancer immunotherapy, where cell populations in the tumor microenvironment and in blood are composed of complex cellular networks comprising many different cell types and phenotypic states.

Designed to capture up to 800 small (5–10 µm) or medium (10–17 µm) cells on the C1, new high-throughput IFCs will enable scientists to profile larger cell populations using the same high-quality Fluidigm workflow that has become an industry standard. We have accelerated the development of a new small-cell high-throughput IFC based on increased customer demand, now planned for release in early Q3. This new IFC incorporates the same high-performing design features as the current small-cell IFC, which has become a mainstay in immunology studies. In early Q4, we plan to release a new medium cell high-throughput IFC that incorporates the same design optimizations as the new medium cell IFC for use with a diverse array of cell types, including cancer cells.

We continue to be amazed by the great discoveries Fluidigm single-cell technologies have helped enable,” said Worthington. “Together with our customers, we will eagerly pursue new insights made accessible by these products.

Source: Fluidigm